Family Formation and Socio-Economic Status among 35-Year-Old Men Who Have Survived Cancer in Childhood and Early Adulthood: A Register-Based Cohort Study
Conclusion: Many men who have survived cancer during childhood or early adulthood are influenced by their cancer later in life, which was apparent in family formation, educational achievements, and labour market attachment. Continued focus on rehabilitation and needs for support among the male survivors of childhood and youth cancer is warranted.Oncol Res Treat (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - November 25, 2021 Category: Cancer & Oncology Source Type: research
The Future Role of PET Imaging in Metastatic Breast Cancer
Background: A variety of therapeutic approaches are employed to treat patients suffering from breast cancer. Likewise, a broad spectrum of imaging ligands has been introduced for non-invasive PET/CT imaging to enable comprehensive tumor characterization and more accurate response evaluation.
Summary: In recent years, novel radioactively labelled ligands have been developed for PET/CT imaging in metastatic breast cancer. One promising tracer is [18F]fluoroestradiol, which was recently approved by the Food and Drug Administration. It can be used for a whole-body assessment of estrogen receptor status. Another radionuclide c...
Source: Oncology Research and Treatment - November 24, 2021 Category: Cancer & Oncology Source Type: research
Diagnostic Value of VDR in Bone Metastasis and Prognosis of Patients with Breast Cancer and Expression Correlation between VDR and Hr
This study aimed to explore the expression of VDR/Hr in breast cancer, and the correlation between VDR/Hr and prognosis, bone metastasis, and metastasis-related prognosis.
Methods: The expression of VDR and Hr was performed on 119 breast cancer tissues and corresponding normal breast tissue from each of the breast cancer samples by Immunohistochemistry (IHC) staining, and the databases were supplemented as well.
Results: The expression of VDR protein was significantly decreased in breast cancer patients (p 0.05) databases showed VDR mRNA expression tended to be higher in tumor tissues. Hr protein was expressed at low lev...
Source: Oncology Research and Treatment - November 24, 2021 Category: Cancer & Oncology Source Type: research
Acceptance and Benefits of Two Different Strategies to Timely Integrate Specialist Palliative Care into Routine Cancer Care – a Randomized Pilot Study
Conclusions: Both SPC integration strategies were well accepted. However, patients seem not to benefit from a brochure in terms of initiating SPC counselling timely after a palliative cancer diagnosis. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - November 24, 2021 Category: Cancer & Oncology Source Type: research
BRAF V600E Mutation in Triple-Negative Breast Cancer: A Case Report and Literature Review
Conclusions: The BRAFV600E mutation may be a potential prognostic factor and therapeutic target for BC.Oncol Res Treat (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - November 24, 2021 Category: Cancer & Oncology Source Type: research
Updated Perspectives on the Management of Relapsed and Refractory Multiple Myeloma
Background: With the availability of T-cell-directed therapy and next-generation compounds of established classes of drugs, the treatment of relapsed/refractory (r/r) myeloma is getting more complex. However, treatment options in practice are limited by availability, approval, and patient comorbidity. The aim of this article is to provide a practical approach toward the choice of treatment for r/r myeloma patients.Summary: Regarding market authorization and current guidelines, at least in Germany, most patients nowadays will have received a doublet or triplet combination as first-line therapy containing a proteasome inhibi...
Source: Oncology Research and Treatment - November 18, 2021 Category: Cancer & Oncology Source Type: research
Metronomic Chemotherapy for Metastatic Breast Cancer
Background: As disease control and quality of life play a leading role in metastatic breast cancer (MBC), metronomic chemotherapy (MCT) is gaining popularity alongside conventional chemotherapy (CCT) and targeted therapies.Summary: MCT, defined as continuous administration of low-dose chemotherapeutic agents, is accepted as a therapy that exerts its effects via immunomodulation, anti-angiogenesis and direct cytotoxic effects. Oral administration of MCT is safe, easy to handle, and allows for flexible drug dosing. Dose accumulations associated with non-tolerable side effects are rare, so the medication can be administered f...
Source: Oncology Research and Treatment - November 18, 2021 Category: Cancer & Oncology Source Type: research
Current Treatment Approaches to Newly Diagnosed Multiple Myeloma
Background: Multiple myeloma is a so far incurable malignant plasma cell disorder. During the past 2 decades, treatment paradigms substantially changed when novel drugs were introduced initially in treatment of relapsed disease and subsequently also in first-line treatment.Summary: Up to now, first-line treatment differs between patients initially classified as transplant eligible and those who are considered as nontransplant eligible. Transplant-eligible patients receive a primary proteasome inhibitor (PI)-based induction which is being combined with an immunomodulating agent and a CD38-directed monoclonal antibody follow...
Source: Oncology Research and Treatment - November 16, 2021 Category: Cancer & Oncology Source Type: research
Multiple Myeloma: The Success Story Continues
Oncol Res Treat (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - November 15, 2021 Category: Cancer & Oncology Source Type: research
Expression of BCRP/ABCG2 Protein in Invasive Breast Cancer and Response to Neoadjuvant Chemotherapy
Conclusions: BCRP/ABCG2 is highly expressed in hormone receptor-positive breast cancer. High BCRP/ABCG2 expression is associated with lymphatic metastasis, tumor size, and poor pCR. BCRP/ABCG2 may be a novel potential biomarker that can predict clinical progression and therapy response after neoadjuvant chemotherapy. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - November 12, 2021 Category: Cancer & Oncology Source Type: research
Multiple Myeloma: Molecular Pathogenesis and Disease Evolution
Background: Multiple myeloma is the second most common hematologic malignancy, which to date remains incurable despite advances in treatment strategies including the use of novel substances such as proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies.Summary: The bone marrow-based disease is preceded by the 2 sequential premalignant conditions: monoclonal gammo pathy of undetermined significance and smoldering myeloma. Plasma cell leukemia and extramedullary disease occur, when malignant clones lose their dependency on the bone marrow. Key genetic features of these plasma cell dyscrasias include chrom...
Source: Oncology Research and Treatment - November 8, 2021 Category: Cancer & Oncology Source Type: research
Low Serological Prevalence of SARS-CoV-2 Antibodies in Cancer Patients at a German University Oncology Center
Conclusion
In the present single center experience, a low serological prevalence of SARS-CoV-2 antibodies among cancer patients even after SARS-CoV-2 infection was found. The results support continued strict preventive measures as well as efforts towards faster vaccination, due to a low immunity level in the population. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - November 1, 2021 Category: Cancer & Oncology Source Type: research
Society Bulletins
Oncol Res Treat 2021;44:651 –658 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - November 1, 2021 Category: Cancer & Oncology Source Type: research
PharmaNews
Oncol Res Treat 2021;44:646 –650 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - November 1, 2021 Category: Cancer & Oncology Source Type: research
PharmaNews
Oncol Res Treat 2021;44:645 –645 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - November 1, 2021 Category: Cancer & Oncology Source Type: research
